• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-3MEF filed by CHF Solutions, Inc.

    3/16/21 9:29:56 PM ET
    $CHFS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CHFS alert in real time by email
    S-3MEF 1 nt10021708x3_s3mef.htm S-3MEF
    As filed with the Securities and Exchange Commission on March 16, 2021
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-3
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    CHF SOLUTIONS, INC.
    (Exact Name of Registrant as Specified in Its Charter)

    Delaware
    (State or Other Jurisdiction of
    Incorporation or Organization)

    68-0533453
    (I.R.S. Employer
    Identification Number)

    12988 Valley View Road
    Eden Prairie, Minnesota 55344
    (952) 345-4200
    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

    Nestor Jaramillo, Jr.
    President and Chief Executive Officer
    CHF Solutions, Inc.
    12988 Valley View Road
    Eden Prairie, Minnesota 55344
    (952) 345-4200
    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service)

    Copies to:

    Phillip D. Torrence
    Honigman LLP
    650 Trade Centre Way, Suite 200
    Kalamazoo, MI 49002
    Tel: (269) 337-7700
    Fax: (269) 337-7703

    Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: [ ]

    If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. [X]

    If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [X] 333-224881

    If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ]

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. [ ]

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. [ ]

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer [ ]
    Accelerated Filer [ ]
    Non-accelerated filer [X]
    Smaller reporting company [X]

    Emerging growth company [ ]  If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. [ ]

    Title Of Each Class Of Securities To Be Registered(1)
    Proposed Maximum
    Aggregate Offering Price
    Amount Of
    Registration Fee(2)
    Common Stock, par value $0.0001 per share
    $          3,479,499.60
    $          379.61

    CALCULATION OF REGISTRATION FEE

    (1)
    The registrant previously registered securities with a maximum aggregate offering price of $30,000,000 on a Registration Statement on Form S-3 (File No. 333-224881), filed on May 11, 2018, and declared effective on May 23, 2018 (the “Prior Registration Statement”). In accordance with Rule 462(b) under the Securities Act of 1933, as amended, (the “Securities Act”), an additional number of securities having a proposed maximum aggregate offering price of $3,479,499.60 is hereby registered. This amount represents no more than 20% of the maximum aggregate offering price of the unsold securities remaining under the Prior Registration Statement. In no event will the maximum aggregate offering price of all securities issued pursuant to this Registration Statement and the Prior Registration Statement exceed that which was registered under such registration statements.
    (2)
    The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act.

    This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b), promulgated under the Securities Act of 1933.



    EXPLANATORY NOTE AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

    This Registration Statement is being filed with the Securities and Exchange Commission (the “Commission”) pursuant to Rule 462(b) of the Securities Act of 1933, as amended (the “Securities Act”). This Registration Statement relates to the Registration Statement on Form S-3 (File No. 333-224881), originally filed with the Commission by CHF Solutions, Inc. (the “Registrant”) on May 11, 2018, and declared effective on May 23, 2018 (the “Prior Registration Statement”). This Registration Statement is being filed for the sole purpose of registering additional securities by a proposed aggregate offering price of $3,479,499.60, which represents no more than 20% of the maximum aggregate offering price of the unsold securities remaining under the Prior Registration Statement. The contents of the Prior Registration Statement, including each of the documents filed by the Registrant with the Commission and incorporated or deemed to be incorporated by reference therein and all exhibits thereto, are hereby incorporated by reference. The required opinions and consents are listed on the exhibit index hereto and filed herewith.

    PART II

    INFORMATION NOT REQUIRED IN PROSPECTUS

    Item 16. Exhibits and Financial Statement Schedules.

    (a) Exhibits. All exhibits filed with or incorporated by reference in the Registration Statement on Form S-3 (SEC File No. 333-224881) are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed herewith, as part of this Registration Statement:

    Exhibit
    Number
    Description
       
    5.1
    Legal Opinion of Honigman LLP.
    23.1
    Consent of Baker Tilly US, LLP.
    23.2
    Consent of Honigman LLP (included in the opinion filed as Exhibit 5.1).


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

    Date: March 16, 2021
    CHF SOLUTIONS, INC.
         
     
    By:
    /S/ NESTOR JARAMILLO, JR.
       
    Nestor Jaramillo, Jr.
       
    President and Chief Executive Officer

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

    Signature
     
    Title
     
    Date
             
    /S/ NESTOR JARAMILLO, JR.
     
    President, Chief Executive Officer and Director
     
    March 16, 2021
    Nestor Jaramillo, Jr.
     
    (principal executive officer)
       
             
    /S/ CLAUDIA DRAYTON
     
    Chief Financial Officer
     
    March 16, 2021
    Claudia Drayton
     
    (principal financial and accounting officer)
       
             
    /S/ STEVEN BRANDT
     
    Director
     
    March 16, 2021
    Steven Brandt
           
             
    /S/ MARIA ROSA COSTANZO
     
    Director
     
    March 16, 2021
    Maria Rosa Costanzo
           
             
    /S/ JOHN L. ERB
     
    Director
     
    March 16, 2021
    John L. Erb
           
           
    /S/ JON W. SALVESON
     
    Director
     
    March 16, 2021
    Jon W. Salveson
           
             
    /S/ GREGORY D. WALLER
     
    Director
     
    March 16, 2021
    Gregory D. Waller
           
             
    /S/ WARREN S. WATSON
     
    Director
     
    March 16, 2021
    Warren S. Watson
           


    Get the next $CHFS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHFS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHFS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant

      EDEN PRAIRIE, Minn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Critically-ill children and babies with kidney failure or who are dependent on artificial kidney support currently do not have enough therapeutic options. Nuwellis (NASDAQ:NUWE) plans to fill this unmet need with the development of a fully integrated pediatric continuous renal replacement therapy (CRRT) device designed to provide care for small babies and children. Nuwellis is a medical device company dedicated to transforming care for patients suffering from fluid imbalance. The new device will build on the existing technology of the company's Aquadex SmartFlow® system, and will be funded in part by a $1.7 million grant from the Nati

      8/5/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

      EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

      7/27/21 4:03:00 PM ET
      $CHFS
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • American Medical Association Issues New CPT Code for Nuwellis' Aquadex Ultrafiltration

      EDEN PRAIRIE, Minn., July 13, 2021 (GLOBE NEWSWIRE) -- In an effort to increase the availability of life-saving ultrafiltration therapy to people experiencing fluid overload, the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT®) code, 0692T for Therapeutic Ultrafiltration. The new CPT code will come into effect on January 1, 2022, at which time providers can utilize the code when using Aquadex® to deliver ultrafiltration to adults and children (20 kg or more). Aquadex is developed and marketed by Nuwellis, Inc. (NASDAQ:NUWE). A specific code for ultrafiltration was granted after a thorough review and validation that the technology met t

      7/13/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Financials

    Live finance-specific insights

    See more
    • Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021

      EDEN PRAIRIE, Minn., July 27, 2021 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), announced today that its second quarter 2021 financial results will be released on Tuesday, August 10, 2021. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview. To access the live webcast, please visit the Investors page of the Nuwellis website at http://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing (877) 303-9826 (U.S.) or (224) 357-2194 (international) and using conference ID: 1396749. An audio archive of the webcast will be available following

      7/27/21 4:03:00 PM ET
      $CHFS
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by CHF Solutions, Inc.

      SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

      3/24/21 11:03:40 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by CHF Solutions, Inc.

      SC 13G - CHF Solutions, Inc. (0001506492) (Subject)

      3/23/21 8:52:19 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - CHF Solutions, Inc. (0001506492) (Subject)

      2/16/21 9:55:44 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuwellis Announces New Appointments to Leadership Team

      EDEN PRAIRIE, Minn., June 22, 2021 (GLOBE NEWSWIRE) -- Continuing its dynamic growth in support of its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload, Nuwellis, Inc. (NASDAQ:NUWE), formerly CHF Solutions, Inc., today announced the appointment of George Montague as Chief Financial Officer, effective June 28, 2021. Neil P. Ayotte, Esq. also joined the Company as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer on June 7, 2021. "Nuwellis is entering an energizing new phase with significant opportunities in heart failure, pediatrics and critical care. The deep knowledge and ex

      6/22/21 8:00:00 AM ET
      $NUWE
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHF Solutions Appoints Nestor Jaramillo, Jr. as President and Chief Executive Officer

      EDEN PRAIRIE, Minn., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the appointment of President and Chief Operating Officer Nestor Jaramillo, Jr. to President and Chief Executive Officer (CEO), effective immediately. Predecessor CEO John Erb will continue to serve as the company’s Chairman of the Board. Mr. Jaramillo joined CHF Solutions in May 2019 and has driven the evolution of the company’s therapeutic focus strategy from solely heart failure to an expansion into critical care and pediatrics. His vision to transform the trajectory of cardiorenal disea

      1/19/21 8:00:00 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by Wotta Paul

      3 - CHF Solutions, Inc. (0001506492) (Issuer)

      4/16/21 11:12:05 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by L John Erb

      4 - CHF Solutions, Inc. (0001506492) (Issuer)

      1/26/21 9:23:33 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by P. Thomas Lynch

      4 - CHF Solutions, Inc. (0001506492) (Issuer)

      1/26/21 9:22:39 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CHFS
    SEC Filings

    See more
    • CHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      4/27/21 8:15:21 AM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by CHF Solutions, Inc.

      DEF 14A - CHF Solutions, Inc. (0001506492) (Filer)

      4/13/21 4:43:22 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CHF Solutions, Inc. filed SEC Form 8-K: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers

      8-K - CHF Solutions, Inc. (0001506492) (Filer)

      4/5/21 5:16:56 PM ET
      $CHFS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care